Dec 14 (Reuters) - Vivus Inc (VVUS.O) said it submitted a briefing document to the U.S. health regulator to address issues raised about its weight-loss drug Qnexa. The company said it would be meeting the endocrine and metabolic division of the Food and Drug Administration in the second half of January to discuss the contents of the proposed resubmission.
